CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

ziprasidone

Trade name: geodon

Small moleculeapproved

Approved

Feb 5, 2001

Ziprasidone is atypical antipsychotic, approved by the U.S. Food and Drug Administration for the treatment of schizophrenia, and acute mania and mixed states associated with bipolar disorder. Intramuscilar injections of Ziprasidone are indicated for rapid control of the agitation in schizophrenic patients. Ziprasidone is used off-label for treatment of major depressive disorder, anxiety, obsessive compulsive disorder, borderline personality disorder. Ziprasidone functions as an antagonist at the D2, 5HT2A, and 5HT1D receptors, and as an agonist at the 5HT1A receptor. — NCATS

Clinical trial activity

120 trials · 94 clinical orgs · 20 marketing orgs

Phase 1
9
Phase 2
46
Phase 3
34
Phase 4
54

Earliest trial started Nov 1, 2000 (NCT00205725)

Timeline

2000s

  1. Jan 1, 2001

    Pfizer — Earliest Phase 3 Sponsor(trial)

  2. Feb 5, 2001

    Pfizer — Earliest FDA Approval

  3. Feb 5, 2001

    Viatris — Marketing Organization

  4. Feb 5, 2001

    Pfizer — NDA Organization

  5. Feb 5, 2001

    Upjohn — Marketing Organization

  6. Feb 5, 2001

    Viatris — NDA Secondary Org

  7. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

  8. Jan 1, 2004

    Dr. Reddy's Laboratories — Earliest Phase 1 Sponsor(trial)

2010s

  1. Mar 2, 2012

    Apotex — Marketing Organization

  2. Mar 2, 2012

    Dr. Reddy's Laboratories — Marketing Organization

  3. Mar 2, 2012

    Lupin — Marketing Organization

  4. Jun 1, 2012

    Sandoz — Marketing Organization

  5. Jun 1, 2012

    Novartis — Marketing Organization

  6. Sep 5, 2012

    Wockhardt — Marketing Organization

  7. Sep 5, 2012

    Chartwell Pharmaceuticals — Marketing Organization

  8. Oct 10, 2013

    Mylan — Marketing Organization

  9. Dec 27, 2016

    Aurobindo Pharma — Marketing Organization

  10. Feb 17, 2017

    Macleods Pharmaceuticals, Ltd — Marketing Organization

  11. Feb 17, 2017

    Neogen — Marketing Organization

  12. Aug 22, 2017

    Cadila Healthcare — Marketing Organization

  13. Aug 22, 2017

    Zydus Discovery DMCC — Marketing Organization

  14. Dec 26, 2019

    Gland Pharma Ltd — Marketing Organization

  15. Dec 26, 2019

    Fosun — Marketing Organization

2020s

  1. Sep 15, 2022

    MSN Laboratories — Marketing Organization

  2. Sep 3, 2025

    STERISCIENCE — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedFeb 5, 2001

Chemistry & pharmacology

Loading structure…

SMILES

ClC1=C(CCN2CCN(CC2)C3=NSC4=C3C=CC=C4)C=C5CC(=O)NC5=C1
Mol. weight
412.936 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
  • cp 88059
  • cp-88059
  • cp-88059
  • cp-88,059
  • cp 88059-01
  • cp-88,059-01
  • cp-880591
  • cp-880591
  • cp-88,059-1
  • cp-88059-1
  • cp-88059-1
  • cp-8805927
  • cp-8805927
  • cp-88059-27
  • cp-88059-27
  • geodon
  • geodon
  • geodon
  • geodon
  • geodon
  • zaprasidone
  • zeldox
  • zeldox
  • ziprasidona
  • ziprasidona
  • ziprasidone
  • ziprasidone
  • ziprasidone
  • ziprasidone
  • ziprasidone
  • ziprasidone
  • ziprasidone
  • ziprasidone
  • ziprasidone
  • ziprasidone
  • ziprasidone hcl
  • ziprasidone hcl
  • ziprasidone hcl
  • ziprasidone hydrochloride
  • ziprasidone hydrochloride
  • ziprasidone hydrochloride
  • ziprasidone hydrochloride
  • ziprasidone hydrochloride
  • ziprasidone hydrochloride, monohydrate
  • ziprasidone mesilate
  • ziprasidone mesylate
  • ziprasidone mesylate
  • ziprasidone mesylate
  • ziprasidone mesylate
  • ziprasidone mesylate
  • ziprasidonum
  • ziprasidonum
  • ziprazidone

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04446234Phase 4May 31, 2021Jiao Tong University
NCT03837860Early Phase 1 (Phase 1)Apr 1, 2019University of Texas, San Antonio
NCT03768726Phase 3Dec 21, 2018Pfizer
NCT03557931Phase 2Jul 13, 2018Astellas
NCT03011645Phase 1Jan 1, 2018Duke University, National Heart, Lung, and Blood Institute (NHLBI)
NCT03781115Phase 1Nov 20, 2017Sidney R. Baer, Jr. Foundation, University of Arizona
NCT04587115Early Phase 1 (Phase 1)Jun 16, 2017University of Texas, San Antonio
NCT02935998Phase 4Oct 1, 2016Beijing HuiLongGuan Hospital, Peking University, Pfizer
NCT02435095Phase 4May 1, 2015RWTH Aachen University
NCT02374567Phase 3Jan 1, 2015Gottfried Wilhelm Leibniz Universität Hannover
NCT02282085Phase 4Dec 1, 2014Otsuka, The University of Texas, Dallas
NCT02307396Phase 4Nov 1, 2014Technical University of Munich
NCT02181803Phase 1Aug 1, 2014Merck
NCT02075047Phase 3May 23, 2014Pfizer
NCT02040883Phase 4Feb 1, 2014Guangzhou Medical University, Guangzhou Psychiatric Hospital
NCT01893229Phase 4Sep 1, 2013Guangzhou Medical University, Guangzhou Psychiatric Hospital, The University of Hong Kong
NCT01844700Phase 4Jul 1, 2013Northwell Health
NCT02650102Phase 1/Phase 2 (Phase 2)Jan 1, 2013Shanxi Medical University
NCT01765829Phase 3Nov 1, 2012Government of Spain, Universidad Carlos III Madrid
NCT02192723N/AJun 1, 2012Peking University
Showing 20 of 120 trials
Page 1 / 6

Organizations

Research & Development (94)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit673952000
National Institute of Mental Health (NIMH)Government8122000
Harvard UniversityAcademic/Hospital6532002
Vanderbilt UniversityAcademic/Hospital5332004
Duke UniversityAcademic/Hospital4342003
Northwell HealthAcademic/Hospital4422002
Washington University in St. LouisAcademic/Hospital4422000
Centro de Investigación Biomédica en Red (CIBER)Academic/Hospital3012005
Peking UniversityAcademic/Hospital3222012
University of CantabriaAcademic/Hospital3312005
University of North Carolina at Chapel HillAcademic/Hospital3122000
University of Texas, San AntonioAcademic/Hospital3322007
Brain & Behavior Research FoundationAcademic/Hospital2022006
Columbia UniversityAcademic/Hospital2122001
Department of Veteran AffairsGovernment2122007
Dr. Reddy's LaboratoriesFor profit2212004
Government of SpainGovernment2122004
Guangzhou Medical UniversityAcademic/Hospital2012013
Guangzhou Psychiatric HospitalAcademic/Hospital2212013
PharmaNet (2006)For profit2012004
94 organizations
Page 1 / 5

Marketing (26)

OrganizationOrg typeRelationshipDate
ApotexFor profitMKTGMar 2, 2012
ApotexFor profitSYNMar 2, 2012
Aurobindo PharmaFor profitSYNDec 27, 2016
Aurobindo PharmaFor profitMKTGDec 27, 2016
Cadila HealthcareFor profitMKTGAug 22, 2017
Chartwell PharmaceuticalsFor profitMKTGSep 5, 2012
Dr. Reddy's LaboratoriesFor profitMKTGMar 2, 2012
FosunFor profitMKTGDec 26, 2019
Gland Pharma LtdFor profitMKTGDec 26, 2019
Gland Pharma LtdFor profitSYNDec 26, 2019
LupinFor profitMKTGMar 2, 2012
MSN LaboratoriesFor profitMKTGSep 15, 2022
Macleods Pharmaceuticals, LtdFor profitMKTGFeb 17, 2017
MylanFor profitMKTGOct 10, 2013
MylanFor profitSYNOct 10, 2013
NeogenFor profitMKTGFeb 17, 2017
NovartisFor profitMKTGJun 1, 2012
PfizerFor profitSYNMar 29, 2006
PfizerFor profitNDAFeb 5, 2001
STERISCIENCEFor profitMKTGSep 3, 2025
SandozFor profitMKTGJun 1, 2012
UpjohnFor profitMKTGFeb 5, 2001
ViatrisFor profitMKTGFeb 5, 2001
ViatrisFor profitNDA2Feb 5, 2001
WockhardtFor profitMKTGSep 5, 2012
Zydus Discovery DMCCFor profitMKTGAug 22, 2017